There were three big evolutions in the history of hair loss treatment. Propecia™ and Rogain™ were launched around 1997, and the history of medical hair loss treatment began.
Around 2003, mesotherapy was applied to hair loss treatment, resulting in another big progress. Early mesotherapy drug prescriptions were mainly recommended by mesotherapy experts, but were not widely available, with components such as 'Biotin, Dexpanthenol, Zinc Biloba, Centella asiatica, Taurine, and Organic silicium'. Various Multi-nutrients prescriptions acting on the TCA Cycle of cells also began to be used for hair loss treatment in the early 2000s. Until then, the main cause of hair loss was DHT, so it was considered the most important means to inhibit 5αR, a DHT reducing agent.
Around 2007, a new fact called Cytokines, which is secreted by DHT, began to be widely shared as the cause of hair loss. Because direct systemic inhibition of DHT has risk of side effects, if some cytokines can work at the local site as antagonists, it would be an ideal treatment. Since Alopecia mechanism is induced at the skin dermis layer, Mesotherapy cytokine therapy can be a new progress for hair loss treatment.
After launching the first cytokines product for alopecia treatment in 2008, AesMed has supplied it to more than 500 hair care clinics in Korea and has improved its products under the medical advice from the client clinics, doctors of key option leader.
From 2011 to 2014, AesMed conducted three clinical trials at two university medical centers, and the results were announced through Journal of Dermatology, World Congress of Hair Research 2013, and 2014.
AGF39™, concluded prescription of AesMed in 2016, is currently the largest model of similar products, and has become a STANDARD model for competitors' product concepts as well as price policies.
As AesMed's AGF39™, it is estimated that at least 3 million procedures have been performed over the past 15 years, and it is currently the most common mesotherapy solution for hair loss treatment in Korea and Japan.
In this way, AesMed's AGF39™ has become the MESOTHERAPY STANDARD for hair loss treatment.
AesMed is currently conducting research for stem cell therapy, which can become a fourth evolution.